Multidrug resistance transporters and modulation

Current Opinion in Oncology

Volumn 12, Issue 5, 2000, Pages 450-458

  Tan, Benjamin ^a   Piwnica Worms, David ^a   Ratner, Lee ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Departments of Medicine Pathology and Molecular Microbiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; ANTIRETROVIRUS AGENT; BIRICODAR; BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; CARRIER PROTEIN; CYCLOSPORIN; CYTARABINE; CYTOTOXIC AGENT; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ELACRIDAR; ETOPOSIDE; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; QUINIDINE; TARIQUIDAR; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; VINCRISTINE; ZOSUQUIDAR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG PENETRATION; HUMAN; KAPOSI SARCOMA; MULTIDRUG RESISTANCE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CYCLOSPORINS; DNA-BINDING PROTEINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PROGNOSIS; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 0034456656     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200009000-00011     Document Type: Review

References (96)

1. Drug resistance in cancer
2. Differences in daunomycin retention in sensitive and resistant P388 leukemic cells as determined by digitized video fluorescence microscopy
3. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells
4. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis
5. P-glycoprotein in pathology: The multidrug resistance gene family in humans
6. Biochemical, cellular, and pharmacological aspects of the multidrug transporter
7. Multidrug resistance in human cancer
8. Genetic and biochemical characterization of multidrug resistance
9. Pharmacology of drugs that alter multiresistance in cancer
10. Functional Imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex
11. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
12. MDR1 Pgp and MRP mediate a drug permeability barrier in choroid plexus epithelium
13. Multidrug resistance protein 1 protects the choiroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier
14. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure
15. Multidrug resistance (mdr1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity
16. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukemias: Biological and clinical implications
17. MDR1 gene expression and treatment outcome in acute myeloid leukemia
18. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy
19. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study
20. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia
21. Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance
22. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2 and p53 as prognostic factors in ovarian carcinomas
23. Expression of P-glycoprotein, a multidrug-resistance gene product, is induced by radiotherapy in patients with oral squaincus cell carcinoma
24. Multi-drug resistance (MDR-1) expression in patients with newly diagnosed AIDS lymphoma
25. Multidrug resistance in lymphomas
26. P-glycoprotein is expressed in Kaposi's sarcoma
27. Overexpression of a novel transporter gene in a multidrug resistant human cancer cell line
28. Multidrug resistance associated with overexpression of MRP
29. Biology of the multidrug resistance associated protein, MRP
30. Transport of glutathione, glucoronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump
31. Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins
32. Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung
33. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia
34. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia
35. Expression of ATP-binding cassette transporters and their role in the secretion of basic fibroblast growth factor and cell survival/apoptosis in Kaposi's sarcoma
36. MRP4: A previously unidentified factor in resistance to nucleoside based antiviral drugs
37. Molecular cloning of cDNA which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes
38. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines
39. A multidrug resistance transporter from human MCF-7 breast cancer cells
40. A human placenta-specific ATP-binding cassette gene (ABOP) on chromosome 4q22 that is involved in multidrug resistance
41. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression
42. Overexpression of the BROP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line
43. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance
44. Early multidrug resistance defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein
45. Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257
46. Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma
47. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia
48. Methods to detect P-glycoprotein·associated multidrug resistance in patients' tumors: Consensus recommendations
49. Tc-99m-sestamibi may be a transport substrate of the human multidrug resistance associated protein (MRP)
50. 99m Tc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein
51. Effects of MDR1 and MDR3 P-glycoproteins, MRP1 and BCRP/MXR/ABCP on transport of 99m Tctetrafosmin
52. Technetium-99m-furifosmin as an agent for functional imaging of multidrug resistance in tumors
53. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m-sestamibi scan in untreated breast cancer patients
54. Fractional retention of technetium-99m-sestamibi as an index of p-glycoprotein expression in untreated breast cancer patients
55. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer
56. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi
57. Modulation of the multidrug resistance P-glycoprotein: Detection with technetium-99m-sestamibi in vivo
58. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients
59. Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: A Phase I/II trial
60. Phase I trial of etoposide with cyclosporin as a modulator of multidrug resistance
61. Phase I trial of doxorubicin with cyclosporin as a modulator of multidrug resistance
62. Comparison of two chemotherapy regimens, with or without cyclosporin A, in relapsed/refractory acute myeloid leukaemia: Results of the U.K. Medical Research Council AML-R trial
63. Benefit of cyclosporin modulation of anthracycline resistance in high-risk AML: A Southwest Oncology Group study
64. Pulsed exposure of SDZ PSC 833 to multidrug resistant P388/ADR and MCF7/ADR cells in the absence of anti-cancer drugs can fully restore sensitivity to doxorubicin
65. Phase I study of paclitaxel in combination with a multidrug resistance modulator PSC 833 (Valspodar), in refractory malignancies
66. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer
67. Valspodar + paclitaxel in advanced breast cancer: A California Cancer Consortium Phase II randomized trial
68. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors
69. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar)
70. Treatment of refractory/relapsed AML with PSC 833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized Phase III trial
71. Phase III study of PSC 833 modulation of multidrug resistance in previously untreated acute myeloid leukemia patients >60 years
72. A phase I trial of doxorubicin, paclitaxel, and PSC 833 as modulator of multidrug resistance in refractory solid tumors
73. A phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral PSC 833 in patients with advanced solid tumors
74. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study
75. Phase II study of PSC 833 and VAD chemotherapy in patients with VAD-refractory multiple myeloma
76. Phase II trial of modified CHOP and PSC 833 for relapsed/refractory intermediate grade non-Hodgkin's lymphoma
77. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors
78. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833
79. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative
80. The acridonecarboxamide GF120918 potently reverses p-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells
81. In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells
82. The mouse Brcp/mxr/abcp gene: Amplifiction and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin
83. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR
84. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein
85. Phase I and pharmacokinetic study targeting a 500 ng/ml plasma concentration of the potent multidrug resistance modulator GF120918 with doxorubicin in patients with advanced solid tumors
86. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979
87. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities
88. Continuous intravenous infusion of LY335979, a P-glycoprotein modulator, administered in combination with doxorubicin: Results of a Phase I dose-escalating trial
89. A Phase I trial of LY335979, a potent multidrug-resistance modulator, administered orally in combination with doxorubicin
90. A Phase I and pharmacokinetic study of docetaxel and LY335979 in patients with advanced malignancies
91. Chemosensitization and drug accumulation effects on VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP
92. Evaluation of pharmacokinetic interactions of VX-710 with doxorubicin and paclitaxel in the beagle dog
93. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP
94. A phase II study of the safety, pharmacokinetics and efficacy of Incel (Biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer
95. New multidrug-resistance reversing drugs, MS-209 and SDZ PSC 833
96. An oral and intravenous Phase I clinical trial of a potent p-glycoprotein modulator, XR9576, in healthy volunteers